114729-69-0

Upstream product

• 107-15-3 ethylenediamine 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 109938-55-8 mono-m-methoxytrityl chloride 

Downstream Products

• 203643-15-6 N-<2-(4-monomethoxytrityl)aminoethyl>aminomethyldiphenyl phosphonate 
• 172405-21-9 methyl N-<2-((4-methoxyphenyl)-diphenylmethyl)aminoethyl> glycinate 
• 170944-06-6 methyl N-<2-((4-methoxyphenyl)-diphenylmethylamino)ethyl>-N-((thymin-1-yl)acetyl) glycinate 
• 172316-36-8 {(2-{[(4-Methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-[2-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid 
• 172405-41-3 methyl N-<2-((4-methoxyphenyl)-diphenylmethylamino)ethyl>-N-<(N²-(isobutanoyl)-guanin-9-yl)acetyl> glycinate 
• 172405-22-0 [[(4-benzoylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-acetic acid methyl ester 
• 203643-39-4 ({(2-{[(4-Methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-[2-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-methyl)-phosphonic acid diphenyl ester 
• 857250-43-2 {[[2-(4-Benzoylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-methyl}-phosphonic acid diphenyl ester 
• 648417-71-4 ({(2-{[(4-Methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-[2-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-methyl)-phosphonic acid 4-methoxy-1-oxy-pyridin-2-ylmethyl ester phenyl ester 
• 857250-44-3 {[[2-(6-Benzoylamino-purin-9-yl)-acetyl]-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-methyl}-phosphonic acid diphenyl ester 
• 203643-17-8 {[[2-(2-Isobutyrylamino-6-oxo-1,6-dihydro-purin-9-yl)-acetyl]-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-methyl}-phosphonic acid diphenyl ester 

Relevant academic research and scientific papers

Dda helicase unwinds a DNA-PNA chimeric substrate: Evidence for an inchworm mechanism

Helicases are ubiquitous enzymes involved in all aspects of DNA metabolism including replication, repair, recombination, and transcription. The mechanism of the bacteriophage T4 Dda helicase was investigated by preparing a DNA-PNA chimeric substrate. Surp

Synthesis and characterization of multifunctional nanovesicles composed of POPC lipid molecules for nuclear imaging

The integration of nuclear imaging analysis with nanomedicine has tremendously grown and represents a valid and powerful tool for the development and clinical translation of drug delivery systems. Among the various types of nanostructures used as drug carriers, nanovesicles represent intriguing platforms due to their capability to entrap both lipophilic and hydrophilic agents, and their well-known biocompatibility and biodegradability. In this respect, here we present the development of a labelling procedure of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine)-based liposomes incorporating an ad hoc designed lipophilic NOTA (1, 4, 7- triazacyclononane-1, 4, 7-triacetic acid) analogue, derivatized with an oleic acid residue, able to bind the positron emitter gallium-68(III). Based on POPC features, the optimal conditions for liposome labelling were studied with the aim of optimizing the Ga(III) incorporation and obtaining a significant radiochemical yield. The data presented in this work demonstrate the feasibility of the labelling procedure on POPC liposomes co-formulated with the ad hoc designed NOTA analogue. We thus provided a critical insight into the practical aspects of the development of vesicles for theranostic approaches, which in principle can be extended to other nanosystems exploiting a variety of bioconjugation protocols.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF

The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

PRODRUGS COMPRISING AN EXENDIN LINKER CONJUGATE

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an exendin linker conjugate D-L, wherein D represents an exendin moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the exendin moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by exendin.

CONJUGATES COMPRISING AN GLP-1/GLUCAGON/GIP TRIPLE RECEPTOR AGONIST, A LINKER AND HYALURONIC ACID

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon/GIP triple receptor agonist, a linker and a hyaluronic acid hydrogel bearing - L1 -L2 - L - Y - R20 groups, wherein Y represents an GLP-1/Glucagon/GIP triple receptor agonist moiety; and -L is a linker moiety - by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon/GIP triple receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon/GIP triple receptor agonist.

CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND

The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition

PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS

The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval

INCREMENTAL DOSE FINDING IN CONTROLLED-RELEASE PTH COMPOUNDS

The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition